Clinical Trials in Ipswich, Australia
7 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Atherosclerotic Cardiovascular Disease (ASCVD)Elevated Lp(a)
Eli Lilly and Company10,450 enrolled751 locationsNCT07157774
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Diabetes Mellitus, Type 1
Eli Lilly and Company300 enrolled132 locationsNCT07222332
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
Arthritis, Psoriatic
Janssen Research & Development, LLC750 enrolled214 locationsNCT06807424
Recruiting
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1151 locationsNCT07064473
Recruiting
The Australian HCV Point-of-Care Testing Program
Hepatitis C
Kirby Institute60,000 enrolled69 locationsNCT05042544
Recruiting
Phase 3
The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect
Chronic Kidney Diseases
The George Institute1,000 enrolled43 locationsNCT06058585
Recruiting
Phase 3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly and Company4,500 enrolled561 locationsNCT07165028
Recruiting
Phase 4
Staphylococcus Aureus Network Adaptive Platform Trial
Staphylococcus Aureus Bacteremia
University of Melbourne8,000 enrolled151 locationsNCT05137119
Recruiting
Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS
MelanomaAtherosclerosis
Monash University130 enrolled12 locationsNCT05180942
Recruiting
Phase 3
Better Evidence and Translation for Calciphylaxis
Calciphylaxis
University of Sydney350 enrolled21 locationsNCT05018221
Recruiting
Phase 4
Randomised Evaluation of Sodium Dialysate Levels on Vascular Events
University of Sydney50,000 enrolled264 locationsNCT02823821
Recruiting
The National Australian HCV Point-of-Care Testing Program - Minimal Dataset
Hepatitis C
Kirby Institute40,000 enrolled11 locationsNCT05248555